Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-Augmented Pump Therapy in the Management of Type 1 Diabetes
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 127
- 试验地点
- 13
- 主要终点
- Time Below 70 mg/dL
研究概览
简要总结
The objective of the study is to assess the efficacy and safety of home use of a Control-to-Range (CTR) closed-loop (CL) system.
详细描述
The protocol is a 3-month parallel group multi-center randomized trial designed to compare Control-to-Range (CTR) closed-loop (CL) with sensor augmented pump therapy (SAP). Approximately 126 subjects will be entered into the randomized trial at approximately seven clinical sites in the United States, such that at least 110 subjects complete the randomized trial. A maximum of 200 subjects may be enrolled in the study in order to achieve the goal of randomizing 126 subjects.
In order to have a broad range of glycemic control among the subjects, a study goal will be to have a minimum of 50 subjects with HbA1c ≥ 7.5% and 50 with HbA1c < 7.5%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year
- •Use of an insulin pump for at least 6 months
- •Age ≥14 years old
- •HbA1c level <10.5% at screening
- •For females, not currently known to be pregnant
- •Willingness not to add glucose-lowering agents (such as Pramlintide, Metformin, GLP-1 analogs, SGLT2 inhibitors) during the study
- •Willingness, if not assigned to the closed-loop group, to avoid use of any closed-loop control system for the duration of the clinical trial
- •Willingness to suspend use of any personal CGM for the duration of the clinical trial once the unblinded study CGM is in use
- •Willingness to establish network connectivity on at least a weekly basis either via local Wifi network or via a study-provided cellular service
- •Currently using no insulins other than one of the following rapid-acting insulins at the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin glulisine (Apidra)
- •Investigator has confidence that the subject can successfully operate all study devices and is capable of adhering to the protocol
- •For subjects less than 18 years old, living with one or more parent/legal guardian (referred to subsequently as diabetes care partner) committed to participating in study training for emergency procedures for severe hypoglycemia and able to contact the subject in case of an emergency
排除标准
- •Medical need for chronic acetaminophen
- •Use of any glucose-lowering agent (such as Pramlintide, Metformin, GLP-1 analogs, SGLT2 inhibitors) in the 3 months prior to enrollment
- •Hemophilia or any other bleeding disorder
- •A condition, which in the opinion of the investigator or designee, would put the participant or study at risk including any contraindication to the use of any of the study devices per FDA labeling
- •Participation in another pharmaceutical or device trial at the time of enrollment or during the study
- •Use of a closed-loop system within the last month prior to enrollment
- •Employed by, or having immediate family members employed by TypeZero Technologies, LLC
结局指标
主要结局
Time Below 70 mg/dL
时间窗: Post randomization (final 11 weeks)
CGM-measured % time below 70 mg/dL - 1st co-primary outcome (superiority)
Time Above 180 mg/dL
时间窗: Post randomization (final 11 weeks)
CGM-measured % time above 180 mg/dL - 2nd co-primary outcome (noninferiority)
次要结局
- Time Below 54 mg/dL(Post randomization (final 11 weeks))
- Time in Range 70-180 mg/dL(Post randomization (final 11 weeks))
- Time in Range 70-140 mg/dL(Post randomization (final 11 weeks))
- Time Above 250 mg/dL(Post randomization (final 11 weeks))
- Time Above 300 mg/dL(Post randomization (final 11 weeks))
- Coefficient of Variation(Post randomization (final 11 weeks))
- Time Below 60 mg/dL(Post randomization (final 11 weeks))